Mckinley Capital Management LLC Genmab A/S Transaction History

Mckinley Capital Management LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$35.27 - $42.24 $151,484 - $181,420	-4,295 Reduced 34.77%	8,058 $284,000
Q2 2023 Aug 09, 2023	SELL	$37.4 - $42.94 $12,716 - $14,599	-340 Reduced 2.68%	12,353 $469,000
Q1 2023 May 11, 2023	SELL	$34.88 - $43.22 $13,707 - $16,985	-393 Reduced 3.0%	12,693 $479,000
Q4 2022 Jan 18, 2023	SELL	$33.8 - $47.06 $14,804 - $20,612	-438 Reduced 3.24%	13,086 $0
Q3 2022 Nov 14, 2022	BUY	$31.52 - $373.61 $426,276 - $5.05 Million	13,524 New	13,524 $434,000
Q1 2021 Apr 21, 2021	SELL	$30.92 - $44.4 $340,367 - $488,755	-11,008 Closed	0 $0
Q4 2020 Feb 10, 2021	SELL	$33.66 - $40.76 $26,726 - $32,363	-794 Reduced 6.73%	11,008 $447,000
Q2 2020 Jul 27, 2020	BUY	$20.05 - $33.89 $236,630 - $399,969	11,802 New	11,802 $400,000

236

52.5M

10.2K

25.5K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.6B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Mckinley Capital Management LLC , based on Form 13F filings with the SEC.

Stay updated on Mckinley Capital Management LLC with notifications on news.